All In Biotech

NDA 219666 · Ptc Therap

Sephience

Sepiapterin · Oral

NovelOrphan

CDER novel approval, Jul 28, 2025: To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet

Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 28, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

2 Phase 3, 2 recruiting

FAERS reports

190

21 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)-restricted diet. SEPHIENCE is a phenylalanine hydroxylase (PAH) activator indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)- restricted diet. ( 1 )

Mechanism: SEPHIENCE is a precursor of the enzymatic co-factor tetrahydrobiopterin (BH 4 ) which activates PAH.

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 28, 2025 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
  • SEPHIENCE · SEPIAPTERIN 1GM/PACKET · POWDER, ORAL · Prescription
  • SEPHIENCE · SEPIAPTERIN 250MG/PACKET · POWDER, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sepiapterin" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product preparation issue55
  • drug ineffective19
  • diarrhoea16
  • abdominal discomfort10
  • amino acid level increased10
  • tooth discolouration10
  • vomiting10
  • abdominal pain upper8
  • headache7
  • skin discolouration7
  • nausea6
  • product preparation error6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20254
2026186

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Ptc Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.